Oncolys BioPharma aims to bring impactful therapeutic candidates to early clinical proof-of-concept for licensing and is committed to expand its pipeline through strategic collaborations. We welcome opportunities to collaborate with research institutes, biotech, and big pharma companies that wish to utilize our oncolytic virus platform.
If you are interested in investment or partnership opportunities, please contact us at:

	Okayama University (Japan)
	Professor Toshiyoshi Fujiwara is a professor of School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University. Professor Fujiwara is co-founder and special advisor of Oncolys BioPharma, and is conducting clinical research for OBP-301 (Telomelysin) at Okayama University.
	Osaka University
	Professor Hiroyuki Mizuguchi is a professor of Graduate School and School of Pharmaceutical Sciences Biochemistry and Molecular Biology, Osaka University. Professor Mizuguchi is a co-inventor of OBP-401 (TelomeScan) and OBP-1101 (TelomeScan F35) *Professor Mizuguchi also holds the post of Chief project leader for Laboratory of Stem Cell Regulation in National Institute of Biomedical Innovation (Japan).
	Kyoto Prefectural University of Medicine (Japan)
	Professor Toshiyuki Sakai is a head of Research Promotion Center and a professor of Division of Preventive Medicine, Kyoto Prefectural University of Medicine. Oncolys BioPharma jointly conducts the research of OBP-801 with Professor Sakai.
	Kagoshima University (Japan)
	Professor Masanori Baba is a professor of Division of Antiviral Chemotherapy at Center for Chronic Viral Diseases, Kagoshima University. Professor Baba is a co-inventor of OBP-601 (Censavudine) and Oncolys BioPharma jointly conducts the research of AI-002 with Professor Baba.
	Astellas Pharma Inc. (Japan)
	Oncolys BioPharma made an exclusive license agreement for OBP-801.
	Yale University (U.S.A.)
	Oncolys BioPharma is granted by Yale University a license for OBP-601 (Censavudine).
	Biologics Consulting Group, Inc. (U.S.A.)
	Oncolys BioPharma receives consulting service on implementing clinical trial based on protocol, filing an IND (Investigational New Drug) application in the U.S.A., dealing with FDA (U.S. Food and Drug Administration).
	Lonza Houston, Inc. (U.S.A.)
	We are in a manufacturing services agreement with Lonza Houston, Inc.
	Medigen Biotechnology Corp. (Taiwan)
	We made a strategic alliance agreement for OBP-301 (Telomelysin) with Medigen Biotechnology Corp.
	Liquid Biotech USA, Inc. (U.S.A.)
	We entered into an exclusive license agreement for OBP-401 in North America with Liquid Biotech USA in 2015.